@article{4570c6b37ce1479d8ea7634bba85e5e6,
title = "Reply to: “A New Approach to the Development of Disease-Modifying Therapies for PD”",
author = "Karl Kieburtz and Olanow, {C. Warren}",
note = "Funding Information: K. Kieburtz is a consultant for Clintrex Research Corp., Roche/Genentech, Novartis, Blackfynn LLC; has received grant support from the NIH (NINDS, NCATS), Michael J. Fox Foundation; has ownership in Clintrex Research Corp., Hoover Brown LLC, Safe Therapeutics LLC. C.W. Olanow CW has given expert testimony for Chevron Corporation; has ownership in Clintrex Research Corporation and Neuro Research Corporation. Relevant conflicts of interest/financial disclosures: ",
year = "2021",
month = may,
doi = "10.1002/mds.28588",
language = "English",
volume = "36",
pages = "1281--1282",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley & Sons Inc.",
number = "5",
}